Acute lymphoblastic leukemia (ALL) is a common hematologic malignancy. Circular RNAs (circRNAs) have been reported as an important factor in regulating cellular process expressed in all hematopoietic compartment. But the molecular mechanism of circRNAs in ALL remain unclear. In this study, we observed circ-0000745 upregulated in leukemia cells (Kasumi-1 and KG-1). Upregulated the expression of circ-0000745 significantly enhanced the proliferation of Kasumi-1 and KG-1 cells, and reduced the ratio of apoptosis cells. Knock down the endogenous expression of circ-0000745 suppressed the cell proliferation and increased the ratio of apoptosis cells. Furthermore, western blot assay showed that overexpression of circ-0000745 increased the activity of ERK1/2. Altogether, these results revealed that upregulated circ-0000745 in leukemia cells could promoter cell viability by increasing the activation of ERK pathway. This study supported the important of circRNAs in the process of acute lymphoblastic leukemia, and provided a new biomarker on ALL diagnosis and therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.gene.2020.144726 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Relapsed childhood T-cell acute lymphoblastic leukemia and lymphoblastic lymphoma.
Haematologica
January 2025
Division of Oncology, the Children's Hospital of Philadelphia, Philadelphia, PA, USA; Department of Pediatrics, the University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.
While outcomes for pediatric acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) have improved dramatically in recent decades, relapsed and refractory disease remain a significant therapeutic challenge. This is particularly true for patients with T-cell ALL and LBL, where survival for patients with relapsed/refractory disease remains dismal. Recent efforts to comprehensively profile the genomics of T-ALL/LBL to improve understanding of disease biology have enhanced our ability to identify high-risk patients at diagnosis who are more likely to relapse and have also identified novel targets for precision medicines.
View Article and Find Full Text PDFTyrosine kinase inhibitor discontinuation in non-allografted Philadelphia-positive acute lymphoblastic leukemia patients: a Campus ALL real-life study.
Haematologica
January 2025
Hematology, Department of Translational and Precision Medicine, Sapienza University of Rome.
Not available.
View Article and Find Full Text PDFNovel classification system and high-risk categories of pediatric acute myeloid leukemia.
Haematologica
January 2025
Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN.
The prognosis of pediatric acute myeloid leukemia (AML) remains poor compared with pediatric acute lymphoblastic leukemia (ALL); accurate diagnosis and treatment strategies based on the genomic background are strongly needed. Recent advances in sequencing technologies have identified novel pediatric AML subtypes, including BCL11B structural variants and UBTF tandem duplications (UBTF-TD), associated with poor prognosis. In contrast, these novel subtypes do not fit into the diagnostic systems for AML of the 5th edition WHO classification or International Consensus Classifications (ICC) released in 2022.
View Article and Find Full Text PDFA case of pityriasis rubra pilaris secondary to ponatinib.
SAGE Open Med Case Rep
January 2025
Departement of Dermatology, Charles-Le Moyne Hospital, Longueuil, QC, Canada.
Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia and acute lymphoblastic leukemia, can cause rare cutaneous side effects. In this case, a 63-year-old woman developed a pityriasis rubra pilaris-like eruption 1 month after starting the drug. The skin reaction improved with dose reduction and recurred more mildly at a lower dose.
View Article and Find Full Text PDFMedicine availability and affordability for paediatric cancers, China.
Bull World Health Organ
January 2025
Department of Pharmacy Administration and Clinical Pharmacy, School of Pharmaceutical Sciences, Peking University, 38 Xueyuan Road, Haidian District, Beijing, 100191, China.
Objective: To investigate access to essential anticancer medicines for children throughout China.
Methods: We obtained cross-sectional drug use data for 2021 from 55 tertiary children's hospitals in seven geographical regions (one third of public children's hospitals in mainland China). Affordability was assessed by comparing the single-day copayment for each medicine with the same generic name and route of administration (i.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!